Bionovo appoints David Boyle CFO
This article was originally published in Scrip
Bionovo, a pharmaceutical company focused on the discovery and development of treatments for women's health and cancer, has appointed David Boyle senior vice-president and chief financial officer. He succeeds Thomas Chesterman, who is leaving the company to pursue other business interests. Mr Boyle was previously senior vice-president and CFO of AVI BioPharma, and vice-president of finance and CFO of XOMA.
You may also be interested in...
Almirall has launched its irritable bowel syndrome drug Constella (linaclotide) in six European countries, with several other launches planned for later this year.
Dermira, a dermatology-focused biotech, has raised $35m in a series B financing.
Clovis Oncology has raised its public offering, announced 11 June, from $170m to $240m.